Atherosclerosis is a systemic disease, affecting all vascular territories throughout the body. The clinical manifestations depend on the affected organ. The clinical consequences of atherosclerosis can dramatically affect the patient population leading to significant impairment of lifestyle, significant morbidity, or even death. The clinical manifestations of atherosclerosis range from angina, myocardial infarction, hypertension, stroke, claudication, critical limb ischemia or limb loss, and death.
Peripheral vascular disease is a common problem especially in the older population. Other patient populations that are considered at high risk include patients with a history of tobacco abuse, diabetes, hypertension, and hypercholesterolemia. Peripheral vascular disease is common in patients seen on a day to day basis in primary care practices as well as practices of cardiovascular specialists, neurologists, podiatrists, nephrologists, endocrinologists, surgeons, etc. It is of great concern that patients with peripheral vascular disease are grossly under recognized.
Attendees will have a better understanding of the epidemiology and prevalence of peripheral vascular disease and be ready to take measures for identification and prevention of progression of this disease in these patients with appropriate risk factor modification. Also, attendees will have a better understanding of current options for treatment and possible new methods for these patients.
Anti-platelet, anti-thrombin, and thrombolytic therapies play a pivotal role in the acute management of patients with acute coronary syndromes, acute MI, and who undergo percutaneous coronary intervention. Recent clinical trial results suggest that oral anti-platelet therapies should be used more broadly in patients presenting with MI, regardless of their initial reperfusion strategy is. It has also become clear that the inherent risk of bleeding associated with appropriate use of powerful anti-thrombotic drugs translates into increased mortality and morbidity both in the short and long term. Optimizing patient selection and careful individual dosing of these potent agents can minimize the risks of bleeding and need for blood products and in turn can improve overall outcomes. In addition, strategies have been developed to conserve blood loss during invasive percutaneous and surgical cardiovascular procedures. The focus of this Symposium is to meet the communities needs to provide rapid, aggressive, and effective anti-thrombotic therapies for acute coronary artery disease, including MI, with the highest level of patient safety and appropriateness of care.
Cardiologists, internists, intensivists, surgeons, ED physicians, podiatrists, nurses, pharmacists and other allied health professionals.
The purpose of the program is to update clinical specialists in the most current concepts in the management of vascular disease and importance of arterial as well as venous thrombembolic disease in cardiovascular, pulmonary, emergency , surgical and obstetrical medicine via new therapies, treatments and research. Case studies and didactic sessions will be part of the format.
Didactic presentations with interactive panel discussions and case studies.
Audience will answer questions during appropriate, designated periods and complete post program survey.
